A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC (PATAGONIA)
A Global, Multicentre, Phase II Platform Study of Datopotamab Deruxtecan (Dato-DXd)-Based Combinations in Adult Participants With TROP2 NMR-positive Non-small Cell Lung Cancer (NSCLC) (PATAGONIA)
Phase II, open-label, multicentre, multi-cohort platform study to determine the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd)-based combinations for the treatment of TROP2 NMR+ NSCLC.
研究概览
详细说明
This is a Phase II, open-label, multicentre, multi-cohort platform study to determine the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd)-based combinations for the treatment of TROP2 NMR+ NSCLC.
This study is designed as non-comparative.
Participants will be randomised to Treatment A or B.
In the module 1 of this study, Dato-DXd-based regimens will be assessed in participants with non-AGA NSCLC whose tumours have been prospectively identified as TROP2 NMR+.
The proposed primary objectives are to assess the efficacy of Dato-DXd combined with durvalumab and carboplatin and Dato-DXd combined with durvalumab in terms of PFS per RECIST 1.1 as assessed by the investigator.
Participants in both treatment groups will receive study treatment medicines until investigator-assessed radiological progression per RECIST 1.1, unacceptable toxicity, withdrawal of consent, or an intervention discontinuation criterion is met. There is no maximum limit to the number of cycles of Dato-DXd and/or durvalumab that a participant in either treatment group can receive. The maximum treatment for carboplatin is 4 cycles.
The study will be conducted in several countries worldwide.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:AstraZeneca Clinical Study Information Center
- 电话号码:1-877-240-9479
- 邮箱:information.center@astrazeneca.com
学习地点
-
-
-
Beijing、中国、100730
- Research Site
-
Beijing、中国、100191
- Research Site
-
Changchun、中国、130021
- Research Site
-
Changsha、中国、410013
- Research Site
-
Chengdu、中国、610041
- Research Site
-
Chongqing、中国、400030
- Research Site
-
Guangzhou、中国、510000
- Research Site
-
Hangzhou、中国、310009
- Research Site
-
Harbin、中国、150081
- Research Site
-
Nanchang、中国、330000
- Research Site
-
Nanning、中国、530021
- Research Site
-
Shandong、中国
- Research Site
-
Shanghai、中国、200032
- Research Site
-
Shanghai、中国、200030
- Research Site
-
Tianjin、中国、300051
- Research Site
-
Wuhan、中国、430022
- Research Site
-
Yangzhou、中国、225001
- Research Site
-
Zhengzhou、中国、450008
- Research Site
-
Zhengzhou、中国、450000
- Research Site
-
-
-
-
Alberta
-
Edmonton、Alberta、加拿大、T6G 1Z2
- Research Site
-
-
Ontario
-
Brampton、Ontario、加拿大、L6R 3J7
- Research Site
-
Toronto、Ontario、加拿大、M4N 3M5
- Research Site
-
-
Quebec
-
Montreal、Quebec、加拿大、H3T 1M5
- Research Site
-
-
-
-
-
Blumenau、巴西、89010-340
- Research Site
-
Curitiba、巴西、80810-050
- Research Site
-
Ijuí、巴西、98700-000
- Research Site
-
Porto Alegre、巴西、90610-000
- Research Site
-
Porto Alegre、巴西、91350200
- Research Site
-
Rio de Janeiro、巴西、22281-100
- Research Site
-
Salvador、巴西、40170-110
- Research Site
-
Santa Maria、巴西、97015-450
- Research Site
-
São Paulo、巴西、01246-000
- Research Site
-
São Paulo、巴西、01509-900
- Research Site
-
São Paulo、巴西、03102-006
- Research Site
-
Teresina、巴西、64049-200
- Research Site
-
Vitória、巴西、29043-260
- Research Site
-
-
-
-
-
Lucca、意大利、55100
- Research Site
-
Orbassano、意大利、10043
- Research Site
-
Parma、意大利
- Research Site
-
Rozzano、意大利、20089
- Research Site
-
Torrette、意大利、60126
- Research Site
-
Verona、意大利、37126
- Research Site
-
-
-
-
-
Singapore、新加坡、119228
- Research Site
-
Singapore、新加坡、308433
- Research Site
-
Singapore、新加坡、217562
- Research Site
-
Singapore、新加坡、168583
- Research Site
-
-
-
-
-
Marseille、法国、13273
- Research Site
-
Nice、法国、06000
- Research Site
-
Paris、法国、75014
- Research Site
-
Paris、法国、75005
- Research Site
-
Pessac、法国、33604
- Research Site
-
Villefranche-sur-Saône、法国、69655
- Research Site
-
-
-
-
-
Lodz、波兰、93-338
- Research Site
-
Lodz、波兰、93-513
- Research Site
-
Przemyśl、波兰、37-700
- Research Site
-
Warsaw、波兰、00-124
- Research Site
-
-
-
-
-
Adelaide、澳大利亚、5000
- Research Site
-
Bedford Park、澳大利亚、5042
- Research Site
-
Southport、澳大利亚、4215
- Research Site
-
Waratah、澳大利亚、2298
- Research Site
-
Woodville、澳大利亚、5011
- Research Site
-
-
-
-
California
-
Irvine、California、美国、92618
- Research Site
-
Oakland、California、美国、94612
- Research Site
-
-
Colorado
-
Golden、Colorado、美国、80401
- Research Site
-
-
Connecticut
-
New Haven、Connecticut、美国、06519
- Research Site
-
-
Florida
-
Miami、Florida、美国、33170
- Research Site
-
Tampa、Florida、美国、33612
- Research Site
-
-
Georgia
-
Atlanta、Georgia、美国、30318
- Research Site
-
-
Illinois
-
Peoria、Illinois、美国、61637
- Research Site
-
-
South Carolina
-
Greer、South Carolina、美国、29651
- Research Site
-
Greer、South Carolina、美国、29650
- Research Site
-
-
Texas
-
Sugar Land、Texas、美国、77479
- Research Site
-
-
Utah
-
Salt Lake City、Utah、美国、84112
- Research Site
-
-
West Virginia
-
Morgantown、West Virginia、美国、26506
- Research Site
-
-
-
-
-
Ciudad Autonoma Buenos Aires、阿根廷、1405
- Research Site
-
Ciudad de Buenos Aires、阿根廷、C1427ARO
- Research Site
-
La Rioja、阿根廷、5300
- Research Site
-
Rosario、阿根廷、2000
- Research Site
-
Rosario、阿根廷、S2000KZE
- Research Site
-
San Juan、阿根廷、5400
- Research Site
-
Viedma、阿根廷、R8500ACE
- Research Site
-
-
-
-
-
Cheongju-si、韩国、28644
- Research Site
-
Jinju、韩国、660-702
- Research Site
-
Seongnam-si、韩国、13620
- Research Site
-
Seoul、韩国、5505
- Research Site
-
Seoul、韩国、120-749
- Research Site
-
Suwon、韩国、16247
- Research Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
INCLUSION CRITERIA:
-
Participant must be ≥ 18 years of age at the time of signing the ICF.
-
Pathologically documented NSCLC that:
- Has documented non-squamous histology
- Is TROP2 NMR positive
- Documented lack of sensitising EGFR mutation, as well as ALK and ROS1 rearrangements on tumour tissue.
-
Stage IIIB or IIIC disease not amenable to surgical resection or definitive chemoradiation, or Stage IV metastatic NSCLC at the time of randomisation, as per the American Joint Committee on Cancer Staging System, 9th Edition.
-
The ECOG PS of 0 to 2.
-
Known tumour PD-L1 status.
-
Minimum life expectancy of 12 weeks.
-
Provision of acceptable FFPE tumour sample from a lesion not previously irradiated.
-
At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 target lesion at baseline.
-
Adequate bone marrow reserve and organ function.
-
Contraceptive use by participants or participant partners.
-
Capable of giving signed informed consent.
-
Provision of signed and dated optional informed consent.
EXCLUSION CRITERIA:
-
As judged by the investigator, any evidence of diseases, chronic diverticulitis or previous complicated diverticulitis, or history of allogenic organ transplant, which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol.
-
History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence, adequately resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin, lentigo maligna that has undergone potentially curative therapy, or adequately treated in situ disease without evidence of disease.
-
Squamous histology or mixed SCLC and NSCLC, or sarcomatoid variant of NSCLC, or lung neuroendocrine tumours .
-
Has documented tumour genomic alterations in EGFR, ALK, ROS1, NTRK, BRAF V600E, RET, MET exon 14, or any other actionable driver oncogenes for which there are locally approved and available targeted first-line therapies.
Note: Participants whose tumours harbour KRAS mutations are eligible for the study
-
Persistent toxicities caused by previous anti-cancer therapy, excluding alopecia or vitiligo, not yet improved to Grade ≤ 1 or baseline.
-
Active or prior documented autoimmune, connective tissue or inflammatory disorders, autoimmune pneumonitis, or autoimmune myocarditis.
-
Spinal cord compression or CNS metastases, unless asymptomatic, stable, and not requiring treatment with corticosteroids or anticonvulsants for at least 7 days prior to randomisation.
-
History of leptomeningeal carcinomatosis or metastasis.
-
Clinically significant corneal disease.
-
Has active or uncontrolled HBV or HCV infection.
-
Known HIV infection that is not well controlled.
-
Uncontrolled infection requiring systemic antibiotics, antivirals, or antifungals, suspected infections or inability to rule out infections.
-
Known to have active tuberculosis infection.
-
Mean resting QTcF > 470 ms, regardless of gender, obtained from triplicate 12-lead ECGs performed at screening.
-
Uncontrolled or significant cardiac disease.
-
History of ILD/pneumonitis.
-
Has clinically severe pulmonary function compromised.
-
Prior exposure to:
- Any agent, including ADC, containing a chemotherapeutic agent targeting topoisomerase I
- Chemotherapy or any other systemic therapy for first-line Stage IIIB, IIIC, or IV NSCLC
- TROP2-targeted therapy
- Chloroquine/hydroxychloroquine without an adequate treatment washout period.
-
Participants who have received any prior adjuvant, neoadjuvant, or definitive chemoradiation for early stage disease (Stage I to III) are eligible, provided they meet the protocol-defined conditions.
-
Current or prior use of immunosuppressive medication within 14 days before the first dose of study intervention.
-
Any concurrent anti-cancer treatment.
-
Any concomitant medication known to be associated with Torsades de Pointes.
-
Receipt of live, attenuated vaccine within 30 days prior to the first dose of study intervention.
-
Received prior radiotherapy to the brain within 2 weeks of start of study intervention or received palliative radiotherapy to the chest within 4 weeks of start of study intervention or has ongoing radiation-related toxicities requiring corticosteroids.
-
Major surgical procedure or significant traumatic injury within ≤ 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
-
Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks prior to randomisation or concurrent participation in another clinical study.
-
Participants with a known history of severe hypersensitivity reactions to study intervention or any excipients of these products.
-
Participants with a known history of severe hypersensitivity reactions to other monoclonal antibodies.
-
Allocation to a stratum that has reached the cap.
-
Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
-
Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
-
For females only: Is pregnant (confirmed with positive serum pregnancy test), or breastfeeding, or planning to become pregnant.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment A
Participants will receive Dato-DXd and durvalumab Q3W on Day 1 of every 21-day cycle. |
Treatment A/B: Dato-DXd as IV infusion.
其他名称:
Treatment A/B: Durvalumab as IV infusion |
|
实验性的:Treatment B
Participants will receive Dato-DXd, durvalumab, and carboplatin Q3W on Day 1 of every 21-day cycle for the first 4 cycles, followed by Dato-Dxd and durvalumab Q3W |
Treatment A/B: Dato-DXd as IV infusion.
其他名称:
Treatment A/B: Durvalumab as IV infusion Treatment B: Carboplatin as IV infusion |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
PFS as assessed by investigator on Treatment A
大体时间:Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months
|
PFS is defined as time from date of first dose of any study treatment until progression per RECIST 1.1 as assessed by the investigator at the local site or death due to any cause. Primary measure of interest is the median PFS. |
Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months
|
|
PFS as assessed by investigator on Treatment B
大体时间:Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months
|
PFS is defined as time from date of first dose of any study treatment until progression per RECIST 1.1 as assessed by the investigator at the local site or death due to any cause. Primary measure of interest is the median PFS. |
Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective Response rate (ORR) in each treatment arm
大体时间:Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months
|
ORR is defined as the proportion of participants who have a confirmed response (CR or PR), as determined by the investigator at local site per RECIST 1.1. For each study treatment group, the primary measure of interest is the estimate of ORR. |
Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months
|
|
Duration of response (DoR) in each treatment arm
大体时间:Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months
|
DoR is defined as the time from the date of first documented confirmed response until the date of documented progression per RECIST 1.1 as assessed by the investigator at the local site or death due to any cause. For each study treatment group, the primary measure of interest is the median DoR. |
Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety as measured by the number of patients with at least one adverse event (AE), by study treatment
大体时间:Date of first dose of study intervention until earliest of 90 days after study treatment discontinuation, death or end of study, up to approximately 30 months
|
Proportion of patients with at least one AE |
Date of first dose of study intervention until earliest of 90 days after study treatment discontinuation, death or end of study, up to approximately 30 months
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- D9260C00007
- 2025 (美国 NIH 拨款/合同)
- 2025-524836-21 (注册表标识符:CTIS (EU))
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared
IPD 共享时间框架
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共享访问标准
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.